The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Feb 25, 2016

Keywords

ClinConnect Summary

The Chinese Hypertrophic Cardiomyopathy Study (CHCS) is a clinical trial aimed at better understanding hypertrophic cardiomyopathy (HCM), a heart condition that causes the heart muscle to thicken. This thickening can lead to serious problems like sudden cardiac death, heart failure, and stroke. The study is especially important because while some genetic causes of HCM are known, many patients still do not have a clear explanation for their condition. The trial will help determine if the current guidelines for assessing the risk of sudden cardiac death, which were created based on studies in Europe and America, are effective for Chinese patients with HCM.

To participate in this trial, individuals must have been diagnosed with HCM, which is indicated by a thickening of the heart's left ventricle. Specifically, they need to have a maximum left ventricle wall thickness of 15 mm or more on an echocardiogram (a type of heart ultrasound) or 13 mm or more if there is a family history of HCM. Those with other heart or systemic diseases that could also cause thickening of the heart muscle will not be included. Participants will have the opportunity to contribute to important research that may lead to better understanding and treatment of HCM in the Chinese population.

Gender

ALL

Eligibility criteria

• • Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM.
• • Exclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.